Kumo Breakout!Bullish Kumo Breakout w/bullish TK cross after a multi-year down trend. Bullish Kumo twist likely to follow over the next few days.Longby IAmSatoshi4
Is this the beginning of a reversal? Pfizer (PFE) experienced a significant surge when they became the first to develop a vaccine against the virus whose name should not be spoken. Afterward, investors took profits, leading to a decline in the stock's chart. Currently, the price has reached the lower band of the parallel channel, suggesting that sellers might switch to buyers. Regarding the indicators: - The 3 Line Indicator shows a reversal, with all three lines forming a triple bottom. The red line (short trend) is already moving higher. - The RSI is breaking out of a channel and pointing straight to the upside, with a bullish divergence in the lower timeframes. - A rare green bullish signal has appeared on the chart, indicating a pivotal moment. This could be the bottom of a long downtrend for Pfizer. I look forward to seeing more developments. #Pfizer Longby ValerianK6
PFE | Time to Accumulate | LONGPfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.Longby DivergenceSeeker4
Pfizer implements $1.5bn cost-cutting initiative. Idea 27/05/24Pfizer Inc. (PFE) has announced a new multi-year plan to reduce operational costs by approximately 1.5 billion USD by the end of 2027. This initiative is in addition to a previously announced 4 billion USD cost reduction strategy in response to decreased investments and a sharp decline in sales from its COVID-19 vaccine. Amid these challenges, Pfizer has actively restructured its operations, including acquiring cancer drug manufacturer Seagen for 43 billion USD, aiming to diversify and strengthen its product portfolio. Despite these financial adjustments, Pfizer has raised its full-year earnings forecast following better-than-expected earnings in Q1. These results were partly attributed to the successful implementation of cost-saving measures. To bolster its financial standing, the company focuses on operational efficiency, restructuring its network, and enhancing its product portfolio. Given this backdrop, let's examine the potential trading opportunities for Pfizer Inc. (NYSE: PFE): On the Daily (D1) timeframe, Pfizer's stock shows a resistance level at 29.65 USD and support at 28.45 USD. The resistance line of the ongoing downtrend has been breached, suggesting a potential shift in market sentiment. If the trend reverses downward, a possible target might be 25.30 USD. If the current uptrend persists, a short-term target is 31.90 USD upon rebounding from the 29.65 USD resistance level. For a medium-term strategy, the stock price could reach 34.10 USD if the upward momentum continues. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.by RoboMarkets3
PFE to take off soonNYSE:PFE Pfizer made a classic reversal and is now in retraction before next move up. Is a long-mid time trade, anyway you will have around 6% dividends on your way as reward for waiting. Longby vladimirvonhalleUpdated 1
Ready to explode!We have everything in place… A double bottom A channel down breakout An inverted head and shoulder forming out Longby balinorUpdated 9912
Pfizer !!! low risk , 20% Gain till next month ?? Hello everyone, today I want to discuss Pfizer's stock which experienced a 58% correction from its peak price and is currently trading around $26. I believe this stock has a lot of potential for both scalpers and long-term investors. With a dividend yield of 6.65% at this price, it's an attractive investment option. Additionally, the earnings report due this week could boost the stock price to $30 by next month. You can refer to the chart for trade stop and stop-loss points. Disclaimer: This information or service is for informational purposes only and is not intended to be personal financial advice #pfizer Longby sepehr_sanjarUpdated 6
Bad idea to go long on PFE?Here I am again with another trade. Pfizer is one of the many stocks I have been following for quite a time waiting for a good setup and I think now it's the time to go long, Bullish RSI divergence, probable double bottom on a long time strong support area. We know this company has received a lot of heat because of covid, but Pfizer is a strong player in the healthcare industry so I hope it will rise again after all this tech AI mania goes over. I'm buying PFE for a swing trade, let's see how it goes in a few months.Longby devdalistudioUpdated 2212
PFE potential buy setupReasons for bullish bias: - The price has broken the downtrend trendline - An entry at the lower highs (LH) breakout will provide further confirmation - Currently, the price is in a consolidation phase Here are the recommended trading levels: Entry Level(Buy stop): 30.18 Stop Loss Level: 25.26 Take Profit Level 1: 35.1 Take Profit Level 2: 40.02 Take Profit Level 3: OpenLongby TradeWithParasUpdated 7
Pfizer Wins $107.5 Million From AstraZeneca in US Cancer DrugPfizer ( NYSE:PFE ) has won $107.5 million in damages from AstraZeneca in a US cancer drug patent trial. A Delaware federal jury found that AstraZeneca's lung cancer drug Tagrisso violated its Wyeth unit's patent rights. The jury agreed that AstraZeneca's drug infringed two patents covering methods for treating cancer with the breast-cancer drug Nerlynx, which is sold by Puma Biotechnology. Puma licenses the patents from Pfizer ( NYSE:PFE ) to make its drug. AstraZeneca, which earned AstraZeneca nearly $5.8 billion in revenue last year, denied infringing the patents and argued they are invalid. Pfizer ( NYSE:PFE ) is no longer a plaintiff in the case. A separate bench trial on some of AstraZeneca's remaining defenses is set to be held in June, which could result in a ruling that negates the verdict. Technical Outlook Pfizer ( NYSE:PFE ) closed Friday's trading at $28.64 down by 0.97%. The stock has a Relative Strength Index (RSI) of 64.11 which is liable for further growth. Pfizer ( NYSE:PFE ) stock is set to rise from its Falling Wedge Pattern which started from the 6th of January, 2024. by DEXWireNews5
PFE potential Buy setupReasons for bullish bias: - Entry at accumulation phase breakout - Bullish Harmonic XABCD pattern on weekly - Strong weekly Bullish divergence - Price broke strong downtrend trendline - Strong bullish weekly candles at support - Positive Earnings Here are the recommended trading levels: Entry Level(CMP): 28.91 Stop Loss Level: 24.65 Take Profit Level 1: 33.17 Take Profit Level 2: 37.43 Take Profit Level 3: OpenLongby TradeWithParas3
$PFE on the moveVery clear picture on NYSE:PFE on a weekly timeframe If it stays above the centre line, the trend is up and I have an initial target of around $35 If takes out the protective stock we have a continuation of the downtrend and this was just a minor upward correction. Risk/Reward ratio 2.90 What's your take on NYSE:PFE from here? Up or DownLongby WavesInvesting0
Breakout confirmed. Upwards nowPrice has broken out of the downward trend. Looks prime to continue upward momentum. RSI's trending up MACD up Are you buying?Longby JK_Market_Recap5
PFIZER, targeting $50! Upside Prospect ON!PFE weekly data is conveying significant accumulation at the current price range. Net positive volume has been increasing on a daily basis for the past few days -- in anticipation of the company's incoming price growth, long term. The stock is currently sitting at 78.6 FIB level -- a discounted level where buyers converge. Expect some significant bounce from the current range with initial target to $50. Weekly higher lows on histogram has been registered. Trend shift is about to commence. First Bubble up volume appearance in almost 2 months. Spotted at 38.0 TAYOR Safeguard capital always.Longby JSALUpdated 447
Accumulation ongoing for PFE - Likely strong upsidePFE has broken out of the downtrend line of 1-year 4 months and has been forming an accumulation. The bullish morning star formation is indicative of a potential rebound going forward. Expect a strong rebound! Longby William-tradingUpdated 10
A Strategic Technical Outlook for Pfizer.Pfizer, Inc. (PFE) has shown a notable rebound in its stock price, as observed in the latest trading sessions. This analysis delves into various technical indicators and chart patterns to forecast future price movements and provide strategic trading recommendations. PFE has recently experienced a bullish surge, evident from the significant green candle that broke above several key resistance levels. This bullish momentum is further corroborated by high trading volume, indicating strong buying interest. Moving Averages: The stock is currently trading above its key moving averages, including the 10-day, 20-day, and 50-day exponential moving averages (EMAs), which are all trending upwards, signaling a bullish outlook in the short term. MACD (Moving Average Convergence Divergence): The MACD line crossing above the signal line suggests increasing bullish momentum. The histogram entering the positive territory further reinforces this bullish sentiment. RSI (Relative Strength Index): The RSI is currently at 64.34, which is near the upper threshold but still below the overbought zone (70), indicating that there is room for upward movement before the stock becomes technically overbought. Stochastic Oscillator: The Stochastic RSI being at 100 indicates overbought conditions on a very short-term basis, suggesting a potential temporary pullback or consolidation may occur before further upward movement. Fibonacci Retracement: The recent surge has pushed the price above the 38.2% Fibonacci retracement level of the last major downswing, targeting the next resistance near the 50% level. Short-Term Bullish Target: If the bullish momentum continues, PFE could test the next resistance at $28.50, marked by the 50% Fibonacci retracement level. A breakout above this level could extend gains towards $29.30, corresponding to the 61.8% retracement level. Support Levels: Immediate support is found at $26.80, with further cushion at $26.20, which aligns with the recent breakout point. Long Entry: Consider going long if the price dips towards $26.80, using a stop loss at $26.20 to protect against unexpected downturns. This position benefits from potential upward movement, with a primary target at $28.50 and a secondary target at $29.30. Short Position: Traders might consider short positions if the price fails to sustain above the $28.50 resistance, with a tight stop loss just above this level at $28.80. The aim would be to capitalize on potential retracements towards the $27.00 mark. Pfizer's technical setup presents a compelling bullish case in the short to medium term, supported by robust volume and favorable technical indicators. However, traders should remain vigilant of potential overbought conditions that could prompt price corrections. Monitoring key resistance and support levels will be crucial for timely trade execution, optimizing both entry and exit points.by AxiomEx7
$pfe bottomingWe're in this from a bit higher. Still holding. We think it's bottoming here. TP 46% from our entry. ~ 56% from here. Would love to swing a weekly SFP today for confirmation, but not really necessary. LTF looks good. Longby drcrypto14Updated 115
Pfizer Inc ideaPfizer Inc idea Safe to enter above $27.18 we may see a new low below $25 Technicals are on positive side.. by XDataAnalyst2
Pfizer Surges as Earnings Soar Above ExpectationsPfizer Inc. ( NYSE:PFE ) sent shockwaves through the market with a stunning first-quarter performance, catapulting its stock price upward following a robust quarterly beat that surpassed analysts' expectations by a wide margin. The pharmaceutical giant reported adjusted earnings of 82 cents per share, significantly outpacing the forecasted 51 cents per share, and raking in $14.88 billion in revenue, well above the anticipated $13.87 billion. This impressive feat marks a stark turnaround from the previous year's earnings of $1.23 per share on $18.49 billion in sales. Investors reacted positively to Pfizer's optimistic outlook for the year, as the company raised its earnings guidance and maintained its sales forecast. With a projected adjusted profit range of $2.15 to $2.35 per share and sales expected to reach between $58.5 billion and $61.5 billion, Pfizer is poised for a strong fiscal year ahead. Key drivers behind Pfizer's stellar performance include aggressive cost-cutting measures and resilient demand for its COVID-19 products, particularly its vaccine Comirnaty, developed in collaboration with BioNTech. Despite a significant drop in sales of the oral antiviral Paxlovid, which fell 50% to $2.04 billion, Pfizer remains optimistic about the prospects of its COVID portfolio, expecting $8 billion in combined sales from its COVID-19 products. The success of Pfizer's strategic acquisitions, notably the $43 billion deal for Seagen, is evident in the robust sales of cancer treatment Padcev and the continued growth of its pipeline. However, challenges persist, as sales of targeted cancer therapy Adcetris fell short of expectations, underscoring the need for sustained new launch performance. Attention is also focused on Pfizer's RSV vaccine, which has faced stiff competition from a rival shot by GSK. Despite lower-than-anticipated sales of Abrysvo, Pfizer ( NYSE:PFE ) remains committed to advancing its respiratory syncytial virus (RSV) vaccine portfolio. Analysts remain cautiously optimistic about Pfizer's trajectory, with JP Morgan's Chris Schott emphasizing the importance of stronger new launch performance and pipeline progress in reshaping investor sentiment.by DEXWireNews3
FDA Approves Pfizer’s First Gene TherapyIn a landmark decision, the Food and Drug Administration (FDA) has given its stamp of approval to Pfizer's groundbreaking gene therapy for hemophilia B, marking a pivotal moment in the field of genetic medicine. Hemophilia B, a rare inherited bleeding disorder affecting thousands in the U.S., has long posed significant challenges for patients and caregivers due to its debilitating nature and the cumbersome treatment regimens it necessitates. Unveiling Beqvez: Pfizer's newly approved gene therapy, Beqvez, heralds a paradigm shift in hemophilia B treatment. Unlike conventional methods that require frequent infusions of factor IX, Beqvez offers a one-time solution, empowering patients to produce the crucial clotting factor independently. This innovative approach not only promises to alleviate the burden of regular treatments but also holds the potential to prevent and control bleeding more effectively. Transformative Impact: The approval of Beqvez represents a ray of hope for individuals grappling with hemophilia B, offering a lifeline towards improved quality of life and reduced medical complexities. Dr. Adam Cuker, from Penn Medicine’s Comprehensive and Hemophilia Thrombosis Program, underscores the transformative potential of Beqvez, emphasizing its ability to mitigate both medical and treatment-related challenges over the long term. Pfizer's Strategic Maneuver For Pfizer ( NYSE:PFE ), the approval of Beqvez marks a strategic triumph in its quest to diversify beyond the realm of COVID therapeutics. With a keen focus on gene and cell therapies, Pfizer ( NYSE:PFE ) is positioning itself at the forefront of medical innovation, aiming to redefine the treatment landscape across various disease domains. The company's investment in Beqvez underscores its commitment to pioneering solutions that address unmet medical needs and enhance patient outcomes. Navigating Challenges: While the approval of Beqvez heralds a new era in hemophilia B treatment, it also presents formidable challenges. The exorbitant price tag of $3.5 million raises concerns about accessibility and affordability, echoing debates surrounding the broader issue of healthcare equity. Furthermore, logistical hurdles and adoption barriers may impede widespread uptake, underscoring the need for comprehensive strategies to ensure equitable access to this groundbreaking therapy. Looking Ahead: As Pfizer ( NYSE:PFE ) embarks on this groundbreaking journey with Beqvez, the company's pipeline continues to brim with promise. From experimental antibodies to gene therapies targeting other genetic disorders like Duchenne muscular dystrophy, Pfizer remains at the vanguard of medical innovation, driving forward the frontier of personalized medicine. As the healthcare landscape evolves, Beqvez stands as a beacon of hope, illuminating a path towards a future where genetic therapies revolutionize the treatment paradigm, one patient at a time.Longby DEXWireNews6
PFE Comeback...?Pfizer staging a comeback to the FWB:30S , let's go! Over investing in COVID and other cash drags pulled them down from the GETTEX:50S , but this may be a good long monthly Call Option play!Longby candlestickninja4
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Despite short-term challenges like revenue and earnings declines in the current quarter, Pfizer (PFE) maintains a positive long-term growth trajectory. With optimistic earnings estimates for the full fiscal year, consistent EPS beats, and a discounted valuation relative to peers, Pfizer represents an attractive investment opportunity. Trade Idea: Buy Pfizer (PFE) Long-term growth potential remains strong despite short-term setbacks. Positive earnings outlook for the full fiscal year indicates resilience. Consistent EPS beats highlight Pfizer's ability to manage its bottom line effectively. Discounted valuation compared to industry peers suggests potential for stock price appreciation. Consider a medium to long-term investment horizon to capture Pfizer's growth prospects and maximize returns.Longby Elite_ForexUpdated 5
PFE could have a Rally towards the Low/Mid 30s Soon!With the fake out rise in the VIX that's now being suppressed back down towards sub $17/$18 prices, I expect a big rally to the low 30s on Pfizer within the next 2-4 weeks. Educational and Informational Purposes Only!Longby candlestickninja5